{"id":"W1970304552","doi":"10.1097/cmr.0b013e32832bbde6","title":"Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma","year":2009,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Neutropenia; Adverse effect; myalgia; Clinical endpoint; Internal medicine; Toxicity; Melanoma; Dacarbazine; Phases of clinical research; Surgery; Chemotherapy; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008042533,0.0009246762,0.001581849,0.0003453001,0.0002940455,0.0005614514,0.0005307976,0.0007893956,0.001846207],"category_scores_gemma":[0.0004184579,0.0004036262,0.0005580192,0.0002990892,0.0003586559,0.0004703039,0.0002365662,0.002115261,0.0005831718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004030026,"about_ca_system_score_gemma":0.0007570707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004240671,"about_ca_topic_score_gemma":0.001465067,"domain_scores_codex":[0.9997854,0.00009742242,0.00001033567,0.00003319651,0.00002814078,0.00004552839],"domain_scores_gemma":[0.999724,0.00004154334,0.00005907518,0.00002795399,0.00001598303,0.0001314637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2976515,0.1565755,0.02542507,0.001214063,0.001118081,0.001003264,0.000787442,0.005359518,0.2264014,0.0004943144,0.004676186,0.2792937],"study_design_scores_gemma":[0.3000133,0.6442072,0.0351527,0.00004563401,0.0003145397,0.0008433068,0.00008831052,0.002750349,0.01171376,0.0001430687,0.004694296,0.00003357603],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943375,0.001790061,0.0006606684,0.0001922013,0.00006819468,0.001618683,0.0003269426,0.00006551436,0.0009402393],"genre_scores_gemma":[0.9917479,0.001605654,0.001664929,0.0003992328,0.0001356181,0.00173633,0.0009082437,0.00002017038,0.001782033],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001846207,"threshold_uncertainty_score":0.006176114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03306034924672339,"score_gpt":0.3534352690582084,"score_spread":0.320374919811485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}